Search results
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Zacks via Yahoo Finance· 6 days agoApellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual...
InMed Pharmaceuticals (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases
Digital Journal· 3 days agoInMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. The company recently released several critical ...
Melatonin may stave off age-related vision loss, study hints
Live Science via Yahoo News· 3 days agoA large new analysis has tied the use of supplemental melatonin to a lower risk of developing one of...
Tackling blindness with focus on vision
China Daily· 17 hours ago"I never expected to not only have my eyes saved, but also continue to save lives in the operating room," said an anesthesiologist surnamed Cheng in Chongqing municipality. After being diagnosed ...
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Update
ETF DAILY NEWS· 9 hours agoOutlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,660,000 ...
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains | Investing.com PH
Investing.com· 3 days agoShares Analysis by The Tokenist (Timothy Fries) covering: Pfizer Inc, Ocuphire Pharma Inc, Rocket...
Professional Faqs: How Long Is Infectious Mononucleosis Contagious?
MSN News· 3 days agoExpert opinion from Ramamurthy Bangalore M.D., F.C.C.P., F.A.C.P., F.A.A.S.M. (Pulmonologist) · 30...
Cantor Fitzgerald Comments on Skye Bioscience, Inc.’s FY2024 Earnings (NASDAQ:SKYE)
ETF DAILY NEWS· 2 days agoSkye Bioscience, Inc. (NASDAQ:SKYE – Free Report) – Investment analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for shares of Skye Bioscience in a research report ...
Discovery in hibernating animals could extend the | Newswise
Newswise· 6 days agoIf the strategy proves clinically successful, it could help increase access to transplantable cells...
Oculis (NASDAQ:OCS) Given New $20.00 Price Target at Bank of America
ETF DAILY NEWS· 6 days agoOculis (NASDAQ:OCS – Get Free Report) had its target price dropped by investment analysts at Bank of America from $21.00 to $20.00 in a note issued to investors on Tuesday, Benzinga reports.
